Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis

Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis

This review analyzes the LIDA trial findings, demonstrating that an abbreviated 3-month romosozumab course followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing costs and treatment burden.
Surgical Fixation Offers No Clinical Benefit and Zero Cost-Effectiveness for Pediatric Medial Epicondyle Fractures: Results from the SCIENCE Trial

Surgical Fixation Offers No Clinical Benefit and Zero Cost-Effectiveness for Pediatric Medial Epicondyle Fractures: Results from the SCIENCE Trial

The SCIENCE multicentre randomized trial demonstrates that surgical fixation for displaced medial epicondyle fractures in children provides no functional advantage over non-surgical care, carries higher complication risks, and is not a cost-effective use of healthcare resources.